November 2, 2016
Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used for treating Alzheimer’s disease (AD). The latest edition of the online peer-reviewed journal Science Translational Medicine published the research first. It included results from the Phase 1 clinical trials in healthy volunteers and people with AD. The safety and efficacy of verubecestat is currently being evaluated in two pivotal Phase 3 clinical trials, EPOCH and APECS, for treating mild-to-moderate AD and prodromal AD, respectively.
Dr. Michael Egan, vice president, clinical development neurosciences, Merck Research Laboratories, said: “The development of a potential disease modifying therapy for treatment of Alzheimer’s disease has long been a focus of biomedical research. We believe this research has the potential to contribute important evidence regarding the amyloid hypothesis, a leading scientific theory for what causes Alzheimer’s disease, and we look forward to seeing the data from our ongoing Phase 3 clinical trials.”